C1480
Z-Phe-Ala fluoromethyl ketone
≥90% (TLC), powder
Synonym(s):
Z-FA-FMK
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
C21H23N2O4F
Molecular Weight:
386.42
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352209
MDL number:
Quality Level
assay
≥90% (TLC)
form
powder
color
white to off-white
solubility
DMSO or DMF: 20 mM
shipped in
dry ice
storage temp.
−20°C
SMILES string
C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)OCc2ccccc2)C(=O)CF
InChI
1S/C21H23FN2O4/c1-15(19(25)13-22)23-20(26)18(12-16-8-4-2-5-9-16)24-21(27)28-14-17-10-6-3-7-11-17/h2-11,15,18H,12-14H2,1H3,(H,23,26)(H,24,27)/t15-,18-/m0/s1
InChI key
ASXVEBPEZMSPHB-YJBOKZPZSA-N
Application
Z-Phe-Ala fluoromethyl ketone (Z-FA-FMK) has been used as a:
- cathepsin inhibitor to study its effects on dendritic cells
- papain-like cysteine protease inhibitor to study its effects on cadmium-induced mitochondrial apoptosis
- cysteine protease inhibitor to study its effects on the interaction of toll-like receptor 9 (TLR9) with granulin in RAW macrophages
Biochem/physiol Actions
Z-Phe-Ala fluoromethyl ketone (Z-FA-FMK) is an inhibitor of cysteine proteases, such as cathepsin B and L. It can also inhibit recombinant effector caspases 2, -3, -6, and -7 and not initiator caspases 8 and -10. Z-FA-FMK plays a role in blocking nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) transactivation. It exhibits therapeutic effects against rheumatoid arthritis.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Transcription factor E3 protects against cadmium-induced apoptosis by maintaining the lysosomal-mitochondrial axis but not autophagic flux in Neuro-2a cells
Pi H, et al.
Toxicology Letters, 295(4), 335-350 (2018)
Man Kyu Shim et al.
Journal of controlled release : official journal of the Controlled Release Society, 294, 376-389 (2018-12-15)
Cancer nanomedicine using nanoparticle-based delivery systems has shown outstanding promise in recent decades for improving anticancer treatment. However, limited targeting efficiency, low drug loading efficiency and innate toxicity of nanoparticles have caused severe problems, leaving only a few available in
Yun-Pei Zhang et al.
American journal of physiology. Gastrointestinal and liver physiology, 311(6), G1091-G1104 (2016-10-30)
LPS-induced microvascular hyperpermeability and hemorrhage play a key role in the development of sepsis, the attenuation of which might be an important strategy to prevent sepsis. However, the current clinical therapies have proven to be inefficient in improving the prognosis
Global Trade Item Number
| SKU | GTIN |
|---|---|
| C1480-3MG | 04061833269497 |